Mind Medicine (MindMed) (MNMD) Expected to Announce Quarterly Earnings on Wednesday

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) is expected to issue its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.31) per share for the quarter. Parties interested in participating in the company's conference call can do so using this link.

Mind Medicine (MindMed) Price Performance

MNMD traded down $0.55 during trading on Friday, hitting $7.63. The company's stock had a trading volume of 2,232,399 shares, compared to its average volume of 3,023,471. The firm's 50 day moving average price is $7.54 and its two-hundred day moving average price is $6.92. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. Mind Medicine has a 12 month low of $4.54 and a 12 month high of $12.22. The stock has a market capitalization of $559.51 million, a price-to-earnings ratio of -3.38 and a beta of 2.59.

Insider Buying and Selling

In other news, CEO Robert Barrow sold 19,106 shares of the company's stock in a transaction that occurred on Thursday, December 26th. The stock was sold at an average price of $7.43, for a total value of $141,957.58. Following the completion of the transaction, the chief executive officer now owns 526,666 shares of the company's stock, valued at $3,913,128.38. This represents a 3.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Dan Karlin sold 6,643 shares of the company's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total value of $49,357.49. Following the completion of the transaction, the insider now directly owns 338,013 shares of the company's stock, valued at $2,511,436.59. This represents a 1.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,022 shares of company stock valued at $208,203 over the last 90 days. 2.26% of the stock is owned by corporate insiders.

Remove Ads

Wall Street Analyst Weigh In

Several research firms have recently commented on MNMD. Evercore ISI began coverage on Mind Medicine (MindMed) in a research note on Tuesday, January 28th. They issued an "outperform" rating and a $23.00 target price for the company. Oppenheimer reissued an "outperform" rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a research note on Tuesday, December 17th. Chardan Capital began coverage on Mind Medicine (MindMed) in a research note on Friday, December 20th. They issued a "buy" rating and a $20.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a research note on Friday, January 31st. Ten investment analysts have rated the stock with a buy rating and three have given a strong buy rating to the stock. According to MarketBeat.com, Mind Medicine (MindMed) has an average rating of "Buy" and a consensus target price of $26.33.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.